# Andrew J Wood

> Andrew J Wood is a startup investor at Advent Life Sciences. See 0 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Advent Life Sciences](https://shizune.co/investors/profile/advent-life)
- Last updated: Aug 2026

Andrew J Wood is a startup investor at Advent Life Sciences. Andrew joined Advent in 2011 after 18 years of experience in the pharmaceutical industry with Eli Lilly & Co. At Lilly, he was initially responsible for clinical development and registration of new molecules, principally in relation to neurological and psychiatric disorders. He then managed both clinical and preclinical discovery organisations,across multiple therapeutic areas, in Europe and in Asia. Latterly, Andrew was leader of Eli Lilly’s in-licensing and business development organisation in Europe. Within this role, he had responsibility for evaluating drug and technology development projects and for structuring collaborations with external partners in the biotechnology sector and in academia.Andrew retired from Eli Lilly in February 2010, since when he has worked as an independent consultant to the pharmaceutical and biotech sectors.Andrew graduated in Natural Sciences from Cambridge University and in Clinical Medicine from the Oxford University Medical School, and spent 10 years in academic medicine before entering the pharmaceutical industry.Andrew has advised several Advent portfolio companies including NeRRe Therapeutics, and is currently a Director of Calcico.

## About Advent Life Sciences

VC Fund · London, United Kingdom

Advent Life Sciences is a venture team investing in life sciences businesses. The team consists of 11 professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The Firm invests in a range of sectors within life sciences,principally in new drug discovery, enabling technologies, and med tech. Realizations in the last three years include Algeta, Avila, CN Creative, EUSA, Micromet. Current investments include Acutus, Biocartis, Cellnovo, f2G, NeRRe,

5 contacts available at Advent Life Sciences.

| Name | Title | Profile |
| --- | --- | --- |
| Andrew J Wood | Venture Partner | https://shizune.co/investors/profile/andrew-j-wood |
| Dale Pfost | General Partner | https://shizune.co/investors/profile/dale-pfost |
| Kaasim Mahmood | General Partner | https://shizune.co/investors/profile/kaasim-mahmood |
| Satish Jindal | General Partner | https://shizune.co/investors/profile/satish-jindal |
| Shahzad Malik | General Partner | https://shizune.co/investors/profile/shahzad-malik |

## FAQ

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co